Advances in Co-registration, Coronary Physiology & Intra Coronary Imaging - November 2023

Prof Javier Escaned is Head of Section (Interventional Cardiology Section) at Hospital Clinico San Carlos / Complutense University (Madrid, Spain). He trained in the United Kingdom as Specialist in Cardiology and obtained his PhD in The Netherlands. Author of >700 indexed scientific articles on interventional cardiology, imaging and physiology (h-index 100) and over 30 years of experience as PCI operator, he regularly lectures and performs live cases at major scientific and educational meetings. He is a recipient of the European Society of Cardiology (ESC) Silver Medal and the Andreas Grüntzig Award for his contributions to the fiedl fo Interventional Cardiology. Main areas of expertise include complex PCI, intracoronary diagnostics and functional coronary angiography. His track record in coronary physiology comprises being investigator on pioneer FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR, and developer of new tools for the assessment of coronary microcirculation. Editorial roles include Deputy Editor EHJ, Advisory Editor Eurointervention, editor of the textbooks “Coronary Stenosis: Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation". Recent board positions include EAPCI board / Education Committee Chair, ESC WG Coronary Pathophysiology and Microcirculation, EuroCTO Board. Recent trials as Principal Investigator include ADVISE II, DEFINE FLAIR, SYNTAX II, PIONEER IV, Cerebral-Coronary-Connection (C3), DCR4Contrast, INOCA LongCovid and AID ANGIO. Additional interests are philosophy and music.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Prof Amir Lerman Is an endowed named Barbara Lips professor of medicine and a consultant in the department of cardiovascular disease at the Mayo graduate school of medicine. Prof. Lerman graduated from the Technion school of Medicine in Haifa Israel and completed his training in internal medicine, cardiovascular diseases and invasive cardiology at the Mayo Clinic Prof. Lerman serves as an associate chair of the department of Cardiovascular medicine and the Director of the Mayo Clinic cardiovascular research center, the medical director of the chest pain and coronary physiology clinic. Prof. Lerman’s interest is the coronary physiology and imaging and the role of novel therapy of the microcirculation and endothelial function in cardiovascular diseases. Prof. Lerman’s research program is also active and publishes in the area regenerative medicine, innovative technologies and digital health. Prof. Lerman published more than 800 manuscripts, book chapters and reviews; the NIH, AHA, and several foundations support his research.

Angela McInerney is an Interventional Cardiologist at University Hospital Galway, Ireland. Following completion of her basic cardiology training in Ireland she was awarded the Brian McGovern Travelling Fellowship grant from the Irish Board for Cardiology Training in 2018 which allowed her to start her interventional fellowship in Hospital Clínico San Carlos, Madrid, Spain. Following two years of coronary training including complex PCI, she was awarded an European Society of Cardiology Fellowship Training Grant and completed a further year of structural intervention also in Clínico San Carlos, Madrid. Her specialist interests are in intracoronary imaging, intracoronary physiology, calcium modification techniques and complex PCI. She has been keenly involved in various research projects pertaining to intracoronary physiology and intravascular imaging having authored and co-authored a number of research articles as well as review articles and book chapters on these topics. During her fellowship she also regularly partook in the preparation and delivery of educational courses in Clínico San Carlos and values the educational aspect of her role as a Consultant Interventional Cardiologist.

Dr Dejan Milasinovic is an interventional cardiologist at the Department of Cardiology, Clinical Center of Serbia. He is also an Assistant Professor at Faculty of Medicine, University of Belgrade. His main research interests focus in the fields of the invasive treatment of acute coronary syndromes and complex coronary interventions, with an emphasis on bifurcation PCI and intracoronary guidance. In 2016, Dr Milasinovic received the EuroPCR 2016 Best Abstract award, for a work on the timing of invasive coronary intervention in patients with non-ST-segment elevation myocardial infarction. He is a member of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and has served as program committee member of the annual EuroPCR conference. Dr Milasinovic also serves on the editorial boards of EuroIntervention (editorial consultant) and PCRonline and is the Chair of the EAPCI Young committee.

Prof. Flavio L. Ribichini is Full Professor of Cardiovascular Medicine and Director of the Division of Cardiovascular Medicine of the University of Verona, where he has served since 2006. Since 2022, he has been a chief of the cardio-thoracic department. Dedicated full time to Interventional Cardiology since 1993, he was Associate Professor of Cardiology and Director of the Catheterization Laboratory of the University Amedeo Avogadro in Novara, Italy from 2002 to 2006. He also worked as a full-time staff cardiologist at the Intensive Care Unit and the Catheterization Unit at Ospedale Santa Croce in Cuneo, Italy in the nineties. Prof. Ribichini obtained his medical degree in 1986 at the National University of Cordoba, Argentina, and then completed his fellowship in Internal Medicine in 1988. He obtained his board certification in Cardiology at the University of Torino, Italy in 1992. He had extensive training around the world in interventional cardiology, including at the University of Paris VII, Henry Mondor Hospital; Stanford University, California; and Mount Sinai Medical School, New York. In addition, he was a awarded a Research Fellowship of the ESC at the OLVZ Cardiovascular Centre, Aalst, Belgium. Prof. Ribichini is the Director of the School of Cardiovascular Medicine and the President of the PhD Department of the University of Verona. He is member of the Editorial Board of the European Heart Journal, member of the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), member ESC Guidelines Task Force, and of the of the scientific committee of the Euro-PCR and the TCT. He is Coordinator, Principle Investigator, and member of the steering committees of several clinical trials and has authored over 350 full publications on clinical and basic cardiovascular research in peer reviewed scientific journals available on PubMed with an H index: 42.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Dr Tim Schäufele is an interventional cardiologist with special interest in CTOs, coronary physiology and calcified lesions. He is owner of Kardiologie-Innenstad Bern private practice and Interventional Cardiologist at Lindenhofspital Bern. Prior to this, he served as Head of Cathlab and Interventional Cardiology at Robert-Bosch-Krankenhaus Stuttgart, after serving as a Research Fellow in Cardiac Magnetic Imaging at the Department of Cardiology University Heidelberg. Dr Schäufele is a Co-Founding Member of Transradial Workingroup German Cardiac Society, a Board Member of the Interventional Working Group of the German Cardiac Society, and a Full Member EuroCTO Club.

Angela McInerney is an Interventional Cardiologist at University Hospital Galway, Ireland. Following completion of her basic cardiology training in Ireland she was awarded the Brian McGovern Travelling Fellowship grant from the Irish Board for Cardiology Training in 2018 which allowed her to start her interventional fellowship in Hospital Clínico San Carlos, Madrid, Spain. Following two years of coronary training including complex PCI, she was awarded an European Society of Cardiology Fellowship Training Grant and completed a further year of structural intervention also in Clínico San Carlos, Madrid. Her specialist interests are in intracoronary imaging, intracoronary physiology, calcium modification techniques and complex PCI. She has been keenly involved in various research projects pertaining to intracoronary physiology and intravascular imaging having authored and co-authored a number of research articles as well as review articles and book chapters on these topics. During her fellowship she also regularly partook in the preparation and delivery of educational courses in Clínico San Carlos and values the educational aspect of her role as a Consultant Interventional Cardiologist.

Dr Dejan Milasinovic is an interventional cardiologist at the Department of Cardiology, Clinical Center of Serbia. He is also an Assistant Professor at Faculty of Medicine, University of Belgrade. His main research interests focus in the fields of the invasive treatment of acute coronary syndromes and complex coronary interventions, with an emphasis on bifurcation PCI and intracoronary guidance. In 2016, Dr Milasinovic received the EuroPCR 2016 Best Abstract award, for a work on the timing of invasive coronary intervention in patients with non-ST-segment elevation myocardial infarction. He is a member of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and has served as program committee member of the annual EuroPCR conference. Dr Milasinovic also serves on the editorial boards of EuroIntervention (editorial consultant) and PCRonline and is the Chair of the EAPCI Young committee.

Prof. Flavio L. Ribichini is Full Professor of Cardiovascular Medicine and Director of the Division of Cardiovascular Medicine of the University of Verona, where he has served since 2006. Since 2022, he has been a chief of the cardio-thoracic department. Dedicated full time to Interventional Cardiology since 1993, he was Associate Professor of Cardiology and Director of the Catheterization Laboratory of the University Amedeo Avogadro in Novara, Italy from 2002 to 2006. He also worked as a full-time staff cardiologist at the Intensive Care Unit and the Catheterization Unit at Ospedale Santa Croce in Cuneo, Italy in the nineties. Prof. Ribichini obtained his medical degree in 1986 at the National University of Cordoba, Argentina, and then completed his fellowship in Internal Medicine in 1988. He obtained his board certification in Cardiology at the University of Torino, Italy in 1992. He had extensive training around the world in interventional cardiology, including at the University of Paris VII, Henry Mondor Hospital; Stanford University, California; and Mount Sinai Medical School, New York. In addition, he was a awarded a Research Fellowship of the ESC at the OLVZ Cardiovascular Centre, Aalst, Belgium. Prof. Ribichini is the Director of the School of Cardiovascular Medicine and the President of the PhD Department of the University of Verona. He is member of the Editorial Board of the European Heart Journal, member of the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), member ESC Guidelines Task Force, and of the of the scientific committee of the Euro-PCR and the TCT. He is Coordinator, Principle Investigator, and member of the steering committees of several clinical trials and has authored over 350 full publications on clinical and basic cardiovascular research in peer reviewed scientific journals available on PubMed with an H index: 42.

Dr Giuseppe Colletti is a specialist in interventional cardiology at the Clinique Saint-Joseph in Arlon, Belgium where his focus is on developing and handling the complex PCI program. He did a fellowship in interventional cardiology at Hôpital Jolimont in La Louvrière, focusing on complex coronary lesions treatment with particular regards to calcified lesions, as well as at the Centre Hospitalier Universitaire de Liège – Sart Tilman. He graduated from medical from the University of Palermo on 2010 and he specialized in cardiology at the University of Sassari in 2016. Dr Colletti has been a published author in peer-reviewed journals and is planning on publishing more in the future as he has been increasingly involved in clinical research.

Prof Javier Escaned is Head of Section (Interventional Cardiology Section) at Hospital Clinico San Carlos / Complutense University (Madrid, Spain). He trained in the United Kingdom as Specialist in Cardiology and obtained his PhD in The Netherlands. Author of >700 indexed scientific articles on interventional cardiology, imaging and physiology (h-index 100) and over 30 years of experience as PCI operator, he regularly lectures and performs live cases at major scientific and educational meetings. He is a recipient of the European Society of Cardiology (ESC) Silver Medal and the Andreas Grüntzig Award for his contributions to the fiedl fo Interventional Cardiology. Main areas of expertise include complex PCI, intracoronary diagnostics and functional coronary angiography. His track record in coronary physiology comprises being investigator on pioneer FFR trials like DEFER (1998), collaborator with Justin Davies in the validation and clinical implementation of iFR, and developer of new tools for the assessment of coronary microcirculation. Editorial roles include Deputy Editor EHJ, Advisory Editor Eurointervention, editor of the textbooks “Coronary Stenosis: Imaging, Structure and Physiology” and “Physiological Assessment of Coronary Stenoses and the Microcirculation". Recent board positions include EAPCI board / Education Committee Chair, ESC WG Coronary Pathophysiology and Microcirculation, EuroCTO Board. Recent trials as Principal Investigator include ADVISE II, DEFINE FLAIR, SYNTAX II, PIONEER IV, Cerebral-Coronary-Connection (C3), DCR4Contrast, INOCA LongCovid and AID ANGIO. Additional interests are philosophy and music.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Dr Lin Wang is an Interventional Cardiology Fellow at Hospital Clinico San Carlos, Madrid, Spain. She is currently undertaking a PHD at the Complutense University of Madrid with a focus in angiographic functional. Lin has an interest in coronary physiology, functional angiography, intracoronary imaging techniques. Lin undertook her cardiology training in CUBA, Centre for Cardiovascular Medicine. She obtained a MPH (Master of Public Health) in hypertensive in 2018 at Universidad Autónoma Madrid.

Dr. Marco Lombardi is an interventional cardiologist at the Azienda Ospedaliero-Universitaria of Alessandria, Italy. He obtained his medical degree from Campus Bio-Medico University of Rome in 2018. He completed his cardiology residency at the Catholic University of the Sacred Heart (Rome, Italy) and pursued an interventional cardiology fellowship at Hospital Clínico San Carlos / Complutense University (Madrid, Spain). Dr. Lombardi also served as a research fellow at the VCU Pauley Heart Center (Richmond, USA) and is currently completing a PhD at the University of Genoa (Genoa, Italy). His main research interests focus on complex PCI, intracoronary physiology and imaging.

Dr Nieves Gonzalo is a Consultant Interventional Cardiologist at Clinico San Carlos University Hospital, Madrid, Spain. She obtained her Specialist Certification in Cardiology after training at Clinico San Carlos University Hospital in Madrid. Subsequently, she underwent a research fellowship at Thoraxcenter, Erasmus University Rotterdam (The Netherlands) focused mainly in intracoronary imaging and bioabsorbable stents. In 2010 she obtained her PhD with the thesis “Optical coherence tomography for the assessment of coronary atherosclerosis and vessel response after stent implantation”. Her track record includes over 170 articles indexed in PubMed, as well as book chapters in Interventional Cardiology textbooks. Recent research projects as principal investigator includes studies about neoatherosclerosis, vessel injury and healing after stent implantation and patterns of calcification in coronary disease. Dr Gonzalo is a dedicated educationalist with involvement in many areas of complex PCI. In 2022, Dr Gonzalo was appointed as a course director for EuroPCR, she also serves as a deputy editor of EuroIntervention, and as a co-chair of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee.

Prof Amir Lerman Is an endowed named Barbara Lips professor of medicine and a consultant in the department of cardiovascular disease at the Mayo graduate school of medicine. Prof. Lerman graduated from the Technion school of Medicine in Haifa Israel and completed his training in internal medicine, cardiovascular diseases and invasive cardiology at the Mayo Clinic Prof. Lerman serves as an associate chair of the department of Cardiovascular medicine and the Director of the Mayo Clinic cardiovascular research center, the medical director of the chest pain and coronary physiology clinic. Prof. Lerman’s interest is the coronary physiology and imaging and the role of novel therapy of the microcirculation and endothelial function in cardiovascular diseases. Prof. Lerman’s research program is also active and publishes in the area regenerative medicine, innovative technologies and digital health. Prof. Lerman published more than 800 manuscripts, book chapters and reviews; the NIH, AHA, and several foundations support his research.

Angela McInerney is an Interventional Cardiologist at University Hospital Galway, Ireland. Following completion of her basic cardiology training in Ireland she was awarded the Brian McGovern Travelling Fellowship grant from the Irish Board for Cardiology Training in 2018 which allowed her to start her interventional fellowship in Hospital Clínico San Carlos, Madrid, Spain. Following two years of coronary training including complex PCI, she was awarded an European Society of Cardiology Fellowship Training Grant and completed a further year of structural intervention also in Clínico San Carlos, Madrid. Her specialist interests are in intracoronary imaging, intracoronary physiology, calcium modification techniques and complex PCI. She has been keenly involved in various research projects pertaining to intracoronary physiology and intravascular imaging having authored and co-authored a number of research articles as well as review articles and book chapters on these topics. During her fellowship she also regularly partook in the preparation and delivery of educational courses in Clínico San Carlos and values the educational aspect of her role as a Consultant Interventional Cardiologist.

Dr Dejan Milasinovic is an interventional cardiologist at the Department of Cardiology, Clinical Center of Serbia. He is also an Assistant Professor at Faculty of Medicine, University of Belgrade. His main research interests focus in the fields of the invasive treatment of acute coronary syndromes and complex coronary interventions, with an emphasis on bifurcation PCI and intracoronary guidance. In 2016, Dr Milasinovic received the EuroPCR 2016 Best Abstract award, for a work on the timing of invasive coronary intervention in patients with non-ST-segment elevation myocardial infarction. He is a member of European Association of Percutaneous Cardiovascular Interventions (EAPCI) and has served as program committee member of the annual EuroPCR conference. Dr Milasinovic also serves on the editorial boards of EuroIntervention (editorial consultant) and PCRonline and is the Chair of the EAPCI Young committee.

Prof. Flavio L. Ribichini is Full Professor of Cardiovascular Medicine and Director of the Division of Cardiovascular Medicine of the University of Verona, where he has served since 2006. Since 2022, he has been a chief of the cardio-thoracic department. Dedicated full time to Interventional Cardiology since 1993, he was Associate Professor of Cardiology and Director of the Catheterization Laboratory of the University Amedeo Avogadro in Novara, Italy from 2002 to 2006. He also worked as a full-time staff cardiologist at the Intensive Care Unit and the Catheterization Unit at Ospedale Santa Croce in Cuneo, Italy in the nineties. Prof. Ribichini obtained his medical degree in 1986 at the National University of Cordoba, Argentina, and then completed his fellowship in Internal Medicine in 1988. He obtained his board certification in Cardiology at the University of Torino, Italy in 1992. He had extensive training around the world in interventional cardiology, including at the University of Paris VII, Henry Mondor Hospital; Stanford University, California; and Mount Sinai Medical School, New York. In addition, he was a awarded a Research Fellowship of the ESC at the OLVZ Cardiovascular Centre, Aalst, Belgium. Prof. Ribichini is the Director of the School of Cardiovascular Medicine and the President of the PhD Department of the University of Verona. He is member of the Editorial Board of the European Heart Journal, member of the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), member ESC Guidelines Task Force, and of the of the scientific committee of the Euro-PCR and the TCT. He is Coordinator, Principle Investigator, and member of the steering committees of several clinical trials and has authored over 350 full publications on clinical and basic cardiovascular research in peer reviewed scientific journals available on PubMed with an H index: 42.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Dr Peter O’Kane graduated from Charing Cross & Westminster Medical School in 1995 with First Class Honours Bachelor of Science BSc degree in Physiology, Medical Degree and numerous prizes including the Llewelyn Prize for the second-best distinction in medical finals. After attaining membership of the Royal College of Physicians he was subsequently awarded a Doctorate of Medicine by the University of London for a thesis on the role of nitric oxide in coronary heart disease. Dr O’Kane was appointed as Consultant Interventional Cardiologist at the Royal Bournemouth Hospital in July 2007. He has performed over 7000 PCI procedures as a Consultant. He routinely treats extensively calcified lesions, bifurcations including left main stem disease & chronic total occlusions. He is committed to teaching & education with local fellowship training program through to national & international proctorship of techniques & multiple adjunctive devices. He has trained Consultant colleagues from the UK, Europe, Asia & USA through local workshops and courses. He is regularly invited as faculty to National & International meetings as a presenter & live case operator. He has published over 70 manuscripts and authored 10 book chapters. He is a local principal Investigator for over 30 National & International multi-centre clinical trials & is dedicated to patient recruitment with over 900 patients recruited to trials he has managed. He has led numerous quality improvement programs, is PCI Lead, Cardiology Governance and Mortality Lead & has achieved National Bronze Clinical Excellence Award level 9. He was a nationally elected member to British Cardiovascular Intervention Society (BCIS) Council (2020-2023) and from March 2023 is a member of BCIS Research Working Group.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Angela McInerney is an Interventional Cardiologist at University Hospital Galway, Ireland. Following completion of her basic cardiology training in Ireland she was awarded the Brian McGovern Travelling Fellowship grant from the Irish Board for Cardiology Training in 2018 which allowed her to start her interventional fellowship in Hospital Clínico San Carlos, Madrid, Spain. Following two years of coronary training including complex PCI, she was awarded an European Society of Cardiology Fellowship Training Grant and completed a further year of structural intervention also in Clínico San Carlos, Madrid. Her specialist interests are in intracoronary imaging, intracoronary physiology, calcium modification techniques and complex PCI. She has been keenly involved in various research projects pertaining to intracoronary physiology and intravascular imaging having authored and co-authored a number of research articles as well as review articles and book chapters on these topics. During her fellowship she also regularly partook in the preparation and delivery of educational courses in Clínico San Carlos and values the educational aspect of her role as a Consultant Interventional Cardiologist.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Dr. Marco Lombardi is an interventional cardiologist at the Azienda Ospedaliero-Universitaria of Alessandria, Italy. He obtained his medical degree from Campus Bio-Medico University of Rome in 2018. He completed his cardiology residency at the Catholic University of the Sacred Heart (Rome, Italy) and pursued an interventional cardiology fellowship at Hospital Clínico San Carlos / Complutense University (Madrid, Spain). Dr. Lombardi also served as a research fellow at the VCU Pauley Heart Center (Richmond, USA) and is currently completing a PhD at the University of Genoa (Genoa, Italy). His main research interests focus on complex PCI, intracoronary physiology and imaging.

Dr Nieves Gonzalo is a Consultant Interventional Cardiologist at Clinico San Carlos University Hospital, Madrid, Spain. She obtained her Specialist Certification in Cardiology after training at Clinico San Carlos University Hospital in Madrid. Subsequently, she underwent a research fellowship at Thoraxcenter, Erasmus University Rotterdam (The Netherlands) focused mainly in intracoronary imaging and bioabsorbable stents. In 2010 she obtained her PhD with the thesis “Optical coherence tomography for the assessment of coronary atherosclerosis and vessel response after stent implantation”. Her track record includes over 170 articles indexed in PubMed, as well as book chapters in Interventional Cardiology textbooks. Recent research projects as principal investigator includes studies about neoatherosclerosis, vessel injury and healing after stent implantation and patterns of calcification in coronary disease. Dr Gonzalo is a dedicated educationalist with involvement in many areas of complex PCI. In 2022, Dr Gonzalo was appointed as a course director for EuroPCR, she also serves as a deputy editor of EuroIntervention, and as a co-chair of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Scientific Documents and Initiatives Committee.

Dr Peter O’Kane graduated from Charing Cross & Westminster Medical School in 1995 with First Class Honours Bachelor of Science BSc degree in Physiology, Medical Degree and numerous prizes including the Llewelyn Prize for the second-best distinction in medical finals. After attaining membership of the Royal College of Physicians he was subsequently awarded a Doctorate of Medicine by the University of London for a thesis on the role of nitric oxide in coronary heart disease. Dr O’Kane was appointed as Consultant Interventional Cardiologist at the Royal Bournemouth Hospital in July 2007. He has performed over 7000 PCI procedures as a Consultant. He routinely treats extensively calcified lesions, bifurcations including left main stem disease & chronic total occlusions. He is committed to teaching & education with local fellowship training program through to national & international proctorship of techniques & multiple adjunctive devices. He has trained Consultant colleagues from the UK, Europe, Asia & USA through local workshops and courses. He is regularly invited as faculty to National & International meetings as a presenter & live case operator. He has published over 70 manuscripts and authored 10 book chapters. He is a local principal Investigator for over 30 National & International multi-centre clinical trials & is dedicated to patient recruitment with over 900 patients recruited to trials he has managed. He has led numerous quality improvement programs, is PCI Lead, Cardiology Governance and Mortality Lead & has achieved National Bronze Clinical Excellence Award level 9. He was a nationally elected member to British Cardiovascular Intervention Society (BCIS) Council (2020-2023) and from March 2023 is a member of BCIS Research Working Group.

Dr Richard A. Shlofmitz, MD, FACC is the Chairman of Cardiology at St. Francis Hospital, The Heart Center®, in Roslyn, New York. A pioneer in interventional cardiology, Dr. Shlofmitz has worked to advance the field, with a focus on optimizing outcomes with the development of Precision PCI. He is a founding co-director of the annual Intravascular Imaging and Coronary Physiology Workshop. Performing over 1,000 coronary interventions annually, he has one of the largest volumes of experience in PCI. He has the most clinical experience with orbital atherectomy and OCT world-wide. His clinical research interests focus on optimizing coronary interventions and he serves on multiple scientific advisory boards and clinical trial steering committees to further this mission. Dr Shlofmitz has been one of the largest enrollers for multiple clinical trials, including TWILIGHT, ILUMIEN III, and Onyx, with more than 75 publications in peer-reviewed journals and was first to perform coronary intravascular lithotripsy (IVL) in North America as part of the DISRUPT CAD III trial.

Dr Tim Schäufele is an interventional cardiologist with special interest in CTOs, coronary physiology and calcified lesions. He is owner of Kardiologie-Innenstad Bern private practice and Interventional Cardiologist at Lindenhofspital Bern. Prior to this, he served as Head of Cathlab and Interventional Cardiology at Robert-Bosch-Krankenhaus Stuttgart, after serving as a Research Fellow in Cardiac Magnetic Imaging at the Department of Cardiology University Heidelberg. Dr Schäufele is a Co-Founding Member of Transradial Workingroup German Cardiac Society, a Board Member of the Interventional Working Group of the German Cardiac Society, and a Full Member EuroCTO Club.

Dr Adrián Jerónimo is an Interventional Cardiology fellow at Hospital Clínico San Carlos in Madrid (Spain). He studied Medicine at Universidad Complutense de Madrid and completed his General Cardiology training at Hospital Clínico San Carlos. He has collaborated in several research projects, including the AID ANGIO study, in which he plays a principal role. His main areas of interest are complex PCI, coronary physiology and intravascular imaging, being part of the CTO programme at Hospital Clínico San Carlos. In addition, he will be finishing his PhD in infective endocarditis and TAVI by the end of 2024.

Dr Breda Hennessey graduated from the Third Faculty of Medicine in Charles University in Prague. Following this, she returned to Ireland to complete her general medical and higher specialist cardiology training. In 2019, she was awarded the Brian McGovern Scholarship by the Irish Cardiac Society, and this allowed her to commence her subspecialty training in Interventional Cardiology at Hospital Clínico San Carlos in Madrid. She completed a two-year coronary interventional fellowship, with a focus on intracoronary imaging, invasive physiology and ultra-low dose contrast intervention. Following completion of her coronary training, she undertook a further fellowship in structural intervention, also at Hospital Clínico San Carlos. In addition to her clinical work, she has been involved in various research projects pertaining to ultra-low dose contrast PCI, investigating the impact of new technologies in reducing contrast burden in complex PCI . She has authored and co-authored a number of research articles, book chapters and has contributed to the European association of Percutaneous Cardiovascular Interventions textbook. During her time at Hospital Clinico San Carlos, she completed a Masters in Interventional Cardiology and is currently undertaking a PHD at the Complutense University of Madrid with a focus in ultra-low dose contrast PCI. Throughout her fellowship, she regularly took part in the preparation and delivery of educational courses, both at Hospital Clinico San Carlos and in collaboration with other tertiary referral centres and international cardiology societies in Spain, the UK and the UAE.

Prof. Flavio L. Ribichini is Full Professor of Cardiovascular Medicine and Director of the Division of Cardiovascular Medicine of the University of Verona, where he has served since 2006. Since 2022, he has been a chief of the cardio-thoracic department. Dedicated full time to Interventional Cardiology since 1993, he was Associate Professor of Cardiology and Director of the Catheterization Laboratory of the University Amedeo Avogadro in Novara, Italy from 2002 to 2006. He also worked as a full-time staff cardiologist at the Intensive Care Unit and the Catheterization Unit at Ospedale Santa Croce in Cuneo, Italy in the nineties. Prof. Ribichini obtained his medical degree in 1986 at the National University of Cordoba, Argentina, and then completed his fellowship in Internal Medicine in 1988. He obtained his board certification in Cardiology at the University of Torino, Italy in 1992. He had extensive training around the world in interventional cardiology, including at the University of Paris VII, Henry Mondor Hospital; Stanford University, California; and Mount Sinai Medical School, New York. In addition, he was a awarded a Research Fellowship of the ESC at the OLVZ Cardiovascular Centre, Aalst, Belgium. Prof. Ribichini is the Director of the School of Cardiovascular Medicine and the President of the PhD Department of the University of Verona. He is member of the Editorial Board of the European Heart Journal, member of the Executive Board of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), member ESC Guidelines Task Force, and of the of the scientific committee of the Euro-PCR and the TCT. He is Coordinator, Principle Investigator, and member of the steering committees of several clinical trials and has authored over 350 full publications on clinical and basic cardiovascular research in peer reviewed scientific journals available on PubMed with an H index: 42.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.

Ziad Ali is the Director of the DeMatteis Cardiovascular Institute, Director of Investigational Interventional Cardiology, and Director of Cardio-nephrology at St Francis Hospital & Heart Center in New York. He is also Director of the Angiographic Core Laboratory at Cardiovascular Research Foundation and Associate Professor of Medicine at Columbia University Medical Center. His clinical research interests focus on the use of intravascular imaging and physiology technologies such as optical coherence tomography, intravascular ultrasound, and flow wire assessment to optimize coronary interventions, for which he has served as a Global principal investigator on a number of trials. Dr. Ali is also a recognized innovator, playing an integral role in the development of the Resting Full-Cycle Ratio (RFR) and Shockwave intravascular lithotripsy. Clinically Dr. Ali developed pioneering techniques to perform vascular interventions without contrast administration, including IVUS-guided zero-contrast PCI and OCT using saline flush media, protecting patients with advanced kidney disease from acute kidney injury and the need for dialysis.

Dr Justin Davies is a board member of Monaco Cardio at the Princess Grace Hospital, Monaco, and an interventional cardiologist with over 15 years of experience as a leading educator in the field. His clinical and academic career was established at Hammersmith Hospital, Imperial College London, where he built an international reputation for innovation in cardiovascular medicine. Over the course of his career, he has successfully mentored 15 PhD students, published more than 500 peer-reviewed papers — including landmark studies in the New England Journal of Medicine and The Lancet — and holds 20 patents in cardiovascular medicine and technology. He was the co-principal investigator of the DEFINE-FLAIR study, which helped establish iFR (Instantaneous Wave-Free Ratio), a diagnostic technique he invented, as a globally adopted standard in coronary physiology. His work reflects a unique blend of scientific innovation, academic leadership, and clinical excellence. In addition to his research and academic commitments, Justin is CEO of Cerebria AI, where he leads the development of next-generation AI-powered cardiovascular imaging and physiology tools. Under his leadership, Cerebria AI is advancing cutting-edge solutions that integrate artificial intelligence with frontline cardiology to enhance clinical decision-making and patient outcomes. Combining deep clinical expertise with entrepreneurial vision, he continues to guide international ventures through funding, regulatory pathways, and commercialization, while remaining committed to transforming cardiovascular care on a global scale.